Table 2.
Effects of probiotics on the clinical manifestations of AD in the different crowd.
| Probiotics | Participants | Outcome | Reference |
|---|---|---|---|
| B. breve M-16V and B. longum BB536 | Pregnant women; N=130 | Probiotics significantly reduced the risk of developing eczema and AD | (95) |
| L. rhamnosus GG, B. animalis subsp. lactis Bb-12, and L. acidophilus La-5 | Pregnant women; N=415 | Probiotic consumption significantly decreased the proportion of Th22 cells and prevented AD in their offspring | (96) |
| Lactobacillus GG ATCC53103 | Pregnant women with a family history of allergy; N=105 | Lactobacillus GG neither reduced the incidence of AD nor altered the severity of AD | (97) |
| L. rhamnosus GG, L. acidophilus La-5, and B. animalis subsp. lactis Bb-12 | Pregnant women; N=415 | Probiotics reduced the cumulative incidence of AD but did not affect atopic sensitization | (98) |
| Bifidobacterium infantis, Streptococcus thermophilus, and Bifidobacterium lactis | Preterm infants; N=1099 | Probiotics did not affect the incidence of allergic diseases and atopic sensitization | (99) |
| L. rhamnosus HN001 | Infants N=474 | L. rhamnosus HN001 exerted the protective effect against eczema when given for the first 2 years only, extend to at least 4 years of age | (100) |
| B. breve M-16V and oligosaccharide mixture | Infants aged <7 months with atopic dermatitis; N=90 | No effect on AD markers | (101) |
| L. rhamnosus MP108 | Children aged 4-48 months with AD; N=66 | L. rhamnosus MP108 decreased the SCORAD socres | (102) |
| L. acidophilus DDS-1, B. lactis UABLA-12 with fructooligosaccharide | Children aged 1-3 years with moderate-to-severe AD; N=90 | The clinical improvement was associated with the administration of the probiotic mixture | (103) |
| L. plantarum CJLP133 | Children aged 12 months to 13 years; N=118 | L. plantarum CJLP133 decreased the SCORAD score and total eosinophil count. IFN-γ and IL-4 were significantly reduced compared to baseline measurements | (104) |
| L. paracasei and L. fermentum | children aged 1-18 years with moderate-to-severe AD | Probiotics significantly improved the clinical symptoms of AD | (105) |
| Lactobacillus pentosus | Children aged 2-13 years; N=82 | Probiotic significantly reduced the SCORAD scores, but the improvement of clinical symptoms had no difference in probiotic and placebo groups | (106) |
| Bifidobacterium lactis CECT 8145, B. longum CECT 7347, and Lactobacillus casei CECT 9104 | Children aged 4 to 17 years with moderate AD; N=50 | The SCORAD index and the use of topical steroids were significantly reduced in the probiotic group compared with the control group | (107) |
| B. animalis subsp lactis LKM512 | Adult patients N=44 | B. animalis subsp lactis LKM512 decreased itch and dermatology specific quality of life scores via kynurenic acid of tryptophan metabolism | (108) |
| Heat-killed L. paracasei K71 | Adult patients N=34 | L. paracasei K71 significantly reduced the skin severity scores | (109) |